OIG: Lack Of 340B Transparency Could Be Costing Part D Plans Millions

The HHS Office of Inspector General says a lack of transparency on which drugs are part of the 340B program may have caused Part D plans to lose tens of millions of dollars in drug rebates from manufacturers in 2014, and the costs to Part D may have increased since because more pharmacies have joined the 340B program. “There is an opportunity to potentially reduce Part D costs if sponsors were to negotiate similar net prices for both non-340B drugs...